PALO ALTO, Calif., Oct. 19, 2017 -- Tesla will post its financial results for the third quarter of 2017 after market close on Wednesday, November 1st, 2017. At that time, Tesla will issue a brief advisory containing a link to the Q3 2017 Update Letter, which will be available on the Tesla IR website. Tesla management will hold a live question and answer webcast that day at 2:30pm Pacific Time (5:30pm Eastern Time) to discuss the Company’s financial and business results and outlook.
| What: | Date of Tesla Q3 2017 Financial Results and Q&A Webcast |
| When: | Wednesday, November 1st, 2017 |
| Time: | 2:30pm Pacific Time / 5:30pm Eastern Time |
| Shareholder Letter: | http://ir.tesla.com |
| Webcast: | http://ir.tesla.com (live and replay) |
Approximately two hours after the Q&A session, an archived version of the webcast will be available on the Company’s website.
For additional information, please visit ir.tesla.com.
Investor Relations Contact: Jeff Evanson Tesla [email protected] Press Contact: Dave Arnold Tesla [email protected]


Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



